HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 09 & 10, September & October 2022 – Toxins and Medicines – Two Sides of the Same Coin       » Utilising Metal Nanoparticles as Plant Growth Regulators to Improve Crop Yield       » Remedy or Poison? How Microplastics Influence Copper Ion Toxicity in Aquatic Plants       » Synthesising Schiff Base Antimicrobial Copper Complexes With Unprecedented Speed       » Enhancing the Understanding of Past Infections With Machine Learning       » Mini, Cellular Bioweapons: Understanding the Structure and Mechanism of Stinging in Sea Anemone Nematocysts       » Converting Dead Spiders Into Gripping Tools
NEWS CRUNCH
Imugene commences first patient dosing of HER-Vaxx Phase 1b/2 Gastric Cancer Study
All eight clinical sites in Asia are actively recruiting. The study is being conducted in Asian countries where there are high rates of gastric cancer and where patients have difficulty accessing expensive antibody treatments such as Herceptin and Perjeta.

Imugene Limited, an immuno-oncology company has announced it has commenced its first patient dosing of the Phase 1b/2 clinical study of its HER-Vaxx immunotherapy in gastric cancer. Patients are currently being enrolled at eight key cancer hospital sites in Asia, including Hong Kong, Thailand and Taiwan.

Imugene is testing a therapeutic anti-cancer vaccine called HER-Vaxx, in HER2+ gastric cancer patients.

Principal investigator, Univ. Professor Dr. Dr.h.c. Christoph Zielinski and Chairman, Clinical Division of Oncology and Department of Medicine at the Medical University Vienna stated, "Our team is excited to be part of this important study and the search for effective new treatments for gastric cancer as there are limited options for patients."

Imugene Chief Executive Officer, Leslie Chong said, "The successful start of this study represents an important development milestone for our business and medical professionals seeking new ways to treat patients with gastric cancer."

HER-Vaxx is designed to produce a strong antibody response against a growth signal receptor protein called HER2 which is found on the cell surface in gastric cancers.

The study is being conducted in Asian countries where there are high rates of gastric cancer and where patients have difficulty accessing expensive antibody treatments such as Herceptin and Perjeta.

Based on preclinical data recently published[1], Imugene believes HER-Vaxx will stimulate a rapid and strong immune response against cancerous cells.

The Phase 1b lead-in trial is testing three different doses of the HER-Vaxx vaccine with up to 18 patients (three groups up to six patients) in combination with chemotherapy across eight trial sites.

The key endpoints are to identify the optimal dose of HER-Vaxx for the Phase II part of the study, and confirm safety. Researchers will monitor the patient's immune responses to the vaccine.

The current study will be followed by a randomised open label Phase II study with around 68 patients with metastatic gastric cancer overexpressing HER2. The study will be randomised into two arms of either HER-Vaxx plus standard-of-care (chemotherapy) or standard-of-care alone. The endpoints of this randomised trial will be safety, immune response, progression-free survival and overall survival.

[1] Joshua Tobias, Joanna Jasinska, Karin Baier, Michael Kundi, Nicholas Ede, Christoph Zielinski, Ursula Wiedermann, Enhanced and long term humoral and cellular immunogenicity of a Her-2/neu hybrid-CRM197 peptide vaccine, using the Th1-driving adjuvant Montanide, BMC cancer, 2017, 17, 118 click here to view

Source: Imugene
FORTHCOMING ISSUE  
What Has Covid Ever Done for Us?
NEWS CRUNCH  
news 2022 PDA Aseptic Processing of Biopharmaceuticals Conference
news Thailand LAB INTERNATIONAL, Bio Asia Pacific, and FutureCHEM INTERNATIONAL are ready to offer the Science and Technology Industry complete solutions this September!
news Better together: registration opens for Vitafoods Asia 2022 co-located with Fi Asia in October
news 2022 PDA Pharmaceutical Manufacturing & Quality Conference
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy